AEterna Zentaris Announces Initiation of a European Multi-Center Phase II trial of D-63153 in Hormone-Dependent Prostate Cancer Apr 11, 2005
Source: AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA LABORATORIES INC.) ... Source: AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA LABORATORIES INC.). (Yahoo Finance -- Biotechnology & Drugs)
AEterna Zentaris Announces Appointments to its Board, as well as to the Board and Management of its Subsidiary Atrium Biotechnologies Dec 15, 2004
" Atrium's Management Appointments Furthermore, the following key management appointments at Atrium were made. John Dempsey is appointed Vice President and Chief Financial Officer. Former Vice President, Finance, Jocelyn Harvey, becomes Vice President, Mergers and Acquisitions. Richard Bordeleau, formerly President at Atrium, is now President, Health and Nutrition Division, while Charles Boulanger is appointed President, Active Ingredients and Specialty Chemicals Division. Finally, Yvan Sergerie... (Canada Newswire)
AEterna Zentaris Receives Regulatory Approval for Impavido(R) in Germany Dec 6, 2004
" About AEterna Zentaris Inc. AEterna Zentaris Inc. is a biopharmaceutical company focused in oncology and endocrine therapy. Its extensive portfolio, from drug discovery to marketed products, includes cetrorelix and perifosine. Cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide(R), is also in advanced clinical development for the treatment of uterine myoma, endometriosis and benign prostatic hyperplasia (BPH). Perifosine, an orally-active... (Canada Newswire)
Canada's Research and Development Spending Down Second Year in a Row - Decrease of 5.1% According to Canada's Top 100 Corporate R&D Spenders List 2004 Oct 28, 2004
For fiscal 2003, 8 companies (Petro-Canada, Labopharm, ID Biomedical, Genpharm, AEterna Laboratories, Vasogen, Cardiome Pharma Honeywell) increased their Rding by more than 50. Petro-Canada, Labopharm and ID Biomedical posted increases in excess of 100. (Canada Newswire)
AEterna Zentaris Enters into a License and Collaboration Agreement with Tulane University for a Novel Class of Potential Anti-Cancer Agents - Growth Hormone Releasing Hormone Antagonists Oct 27, 2004
" "The addition of GH-RH antagonists, which may offer broad therapeutic utility as anti-cancer agents and endocrine therapy, represents an important step in our continued effort on building a strategic portfolio in oncology and endocrinology, our current areas of focus," concluded Mr. Gilles Gagnon, President and Chief Executive Officer of AEterna Zentaris. GH-RH is a hormone secreted in the brain by the hypothalamus that acts on the pituitary gland to stimulate the synthesis and the release of... (Canada Newswire)
Theratechnologies: New President and Chief Executive Officer Appointed Oct 22, 2004
At the time of the merger between Rhone-Poulenc Rorer and Hoechst Marion Roussell to form Aventis Pharma in 1999, Mr. Rosconi was President and General Manager of Rhone-Poulenc Rorer Canada, Inc. He spent the next two years as Senior Vice-President and Chief Operating Officer of Aeterna Laboratories in Quebec City before re-joining Aventis in 2001 as Senior Vice President - Aventis Intercontinental Africa Middle East. Speaking on behalf of the Board of Directors of Theratechnologies, Company... (PR Newswire)
Earnings Section Oct 19, 2004
Canadian Press - Wed Aug 11,10:38 AM ET QUEBEC (CP) - AEterna Zentaris Inc., formerly AEterna Laboratories, has reported second-quarter earnings of 1. 3 million, helped by a 6. (Yahoo News -- Business)
AEterna Zentaris Reports Statistically Significant Positive Phase II Data on Cetrorelix in Benign Prostatic Hyperplasia Oct 7, 2004
We believe that the results of the extensive Phase II program will now allow us to finalize the development plans for the compound," stated Dr. Werner Cautreels, Solvay Pharmaceuticals' Global Head of R The randomized, double-blind, placebo-controlled trial enrolled patients with symptomatic and objectively defined BPH (decreased urine flow) and was conducted in Europe, under the coordination of Professor Frans MJ Debruyne from the Department of Urology, University Medical Center in Nijmegen.... (Canada Newswire)
AEterna Zentaris Enters a License and Collaboration Agreement with Spectrum Pharmaceuticals on Fourth Generation LHRH Antagonist D-63153 after Zentaris Regains Worldwide Rights to D-63153 from Baxter Healthcare Aug 12, 2004
AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA LABORATORIES INC.) - More on this organization. Quotes & Charts. (Canada Newswire)
Canada NewsWire Daybook for Wednesday, May 26, 2004 ALL TIMES ARE ... May 26, 2004
---------------------------------------------------------------- NOVA SCOTIA TIME: 3:00 p.m. EVENT: CUPE LOCAL 3912 MEMBERS ARE INVITED TO ATTEND AN INFORMATION MEETING LOCATION: Dal Student Union Building, Dalhousie University, HALIFAX CONTACT: Barb Kowalski, (902) 455-4180 MSG NO.: c6178 - 05/20/2004 URL: ---------------------------------------------------------------- QUEBEC TIME: 8:00 a.m. EVENT: DEMONSTRATION BY FEDERAL CORRECTIONAL OFFICERS DURING A CAMPAIGN EVENT BY PRIME MINISTER PAUL... (CNW Telbec, Canada)
AEterna Laboratories Holds 2004 Annual Shareholder Meeting and Announces Company Name Change to AEterna Zentaris May 26, 2004
All amounts are in Canadian dollars MONTREAL, May 26 /CNW Telbec/ - At the Annual Shareholder Meeting today, Gilles Gagnon, President and Chief Executive Officer of AEterna Laboratories Inc. (TSX: AEL, NASDAQ: AELA) unveiled the Company's new corporate name, AEterna Zentaris Inc., as approved by shareholders ... Shareholder meeting highlights Corporate name change - AEterna Laboratories Inc. changes its name to AEterna Zentaris Inc. Marketed Products - Cetrotide(R) (cetrorelix) - Signed... (Canada Newswire)
Aeterna, Lions Gate, Petro-Canada: Canadian Equity Preview May 25, 2004
Aeterna Laboratories Inc. (AEL CN): The company said it will present positive Phase II trial results later today for cetrorelix, a treatment for endometriosis. The results will trigger an undisclosed ``milestone'' payment by partner Solvay Pharmaceuticals Inc., Aeterna said in a PRNewswire release. (Bloomberg)
AEterna/Zentaris to Present Today Additional Detailed Positive Phase II Data on Cetrorelix in Gynecological Indications at the 18th World Congress of the International Federation of Fertility Societies (IFFS) May 25, 2004
QUEBEC CITY, May 25 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA), along with its wholly-owned subsidiary Zentaris GmbH, announced today that the Company will present further detailed positive Phase II data on cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in endometriosis and pre-surgical treatment of uterine myomas at today's session of the World Congress of the International Federation of Fertility Societies (IFFS) being held in Montreal ... About... (Canada Newswire)
CALENDAR May 24, 2004
AEterna Laboratories Inc. shareholders meet in Montreal. Earnings reports. (Globe and Mail -- BusinessTP)
AEterna to Present at UBS Global Specialty Pharmaceuticals Conference May 24 and Annual Shareholder Meeting to be held May 26 May 19, 2004
QUEBEC CITY, May 19 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA) announced today that Gilles Gagnon, President and Chief Executive Officer of the Company will present a corporate update at the UBS Global Specialty Pharmaceuticals Conference at 8:30 a.m. ET on Monday, May 24, 2004, which will be held at the Grand Hyatt Hotel in New York City ... About AEterna Laboratories Inc. AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH, is a... (Canada Newswire)
AEterna/Zentaris to Present Detailed Positive Phase II Data on Cetrorelix and New Preclinical Data on Perifosine during Investor and Analyst Day in New York City May 17, 2004
Headline positive Phase II data on cetrorelix were reported on April 29, 2004, with additional detailed Phase II data in endometriosis and pre-surgical treatment of uterine myomas to be presented at the 18th World Congress of the International Federation of Fertility Societies (IFFS) on May 23-28, 2004 QUEBEC CITY, Canada, May 17 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA), along with its wholly-owned subsidiary Zentaris GmbH, today announced that it will present detailed... (Canada Newswire)
AEterna Laboratories added to NASDAQ Biotech Index May 17, 2004
QUEBEC CITY, QC, May 17 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA) today announced that it has been selected to be added to the NASDAQ Biotechnology Index (NBI) effective on Monday, May 24, 2004 ... About AEterna Laboratories AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company focused in oncology and endocrine therapy ... For further information: AEterna Laboratories: Paul Burroughs, Media Relations, (418)... (Canada Newswire)
FRI May 14, 04, 6:30 PM May 15, 2004
Company Briefs AEterna Laboratories Inc. (Nasdaq: ) has a portfolio of marketed and development-stage biopharmaceutical products. The Company's products include Neovastat, an angiogenesis inhibitor in clinical trials for renal cell and non-small cell lung cancers, and Cetrotide, an IVF product. (PR Newswire)
AEterna Laboratories to Hold Investor and Analyst Day on May 17, 2004 in New York City May 11, 2004
The meeting will be held at the St. Regis Hotel and will start at 1:15 p.m. EDT QUEBEC CITY, May 11 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA), along with its wholly-owned subsidiary Zentaris GmbH, today announced plans to host an Investor and Analyst Day on Monday, May 17, 2004 from 1:15 p.m. - 4:00 p.m. EDT at the St. Regis Hotel in New York City ... About AEterna Laboratories AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH, is a... (Canada Newswire)
Stock markets mixed as Fed signals higher interest rates are in ... May 5, 2004
AEterna Laboratories shares lost 54 cents to $10. 31 even as the firm cut its first quarter loss to $2. (National Post, Canada)
Resource stocks drive TSX up almost 200 points; Dow flat as Fed stands pat May 5, 2004
Aeterna Laboratories lost 45 cents to $10. 40 even it cut its first-quarter loss to $2. (CJAD 800, Canada)
Canada NewsWire Daybook for Tuesday, May 4, 2004 ALL TIMES ARE LOCAL May 4, 2004
INTERNET: CONTACT: Elaine Gosnell, 1-864-597-0142 MSG NO.: c5444 - 04/26/2004 URL: TIME: 10:00 a.m. Eastern EVENT: WEBCAST/CONFERENCE CALL - AETERNA LABORATORIES FIRST QUARTER FINANCIAL RESULTS PHONE NO.: 416-640-4127, 514-807-8791 or 1-800-814-4890 INTERNET: or CONTACT: Paul Burroughs, (418) 652-8525 ext. 406 MSG NO.: c6121 - 04/28/2004 URL: TIME: 10:00 a.m. Eastern EVENT: WEBCAST/CONFERENCE CALL - RDM CORPORATION Q2 RESULTS PHONE NO.: 1-800-387-6216 or 416-405-9328; REFERENCE NUMBER: 3045646... (Canada Newswire)
AEterna Laboratories Reports First Quarter 2004 Financial and Operating Results May 4, 2004
6 million All amounts are in Canadian dollars QUEBEC CITY, May 4 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA) today reported financial results for the first quarter ended March 31, 2004 ... About AEterna Laboratories AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company with an extensive product portfolio, including two marketed products and 14 other product candidates under development in oncology, endocrinology and... (Canada Newswire)
Carmakers to release US sales figures May 3, 2004
Also reporting earnings are biopharmaceutical firm Stressgen Biotech, the Bell Nordiq Income Fund and Aeterna Laboratories. In Toronto, the Great Lakes Hydro. (Montreal Gazette, Canada)
Earnings avalanche May 2, 2004
Also reporting earnings are biopharmaceutical firm Stressgen Biotech, the Bell Nordiq Income Fund and Aeterna Laboratories. In Toronto, the Great Lakes Hydro Income Fund and Magna Entertainment hold annual meetings. (Toronto Star, Canada)
AEterna Laboratories Announces First Quarter Financial Results Conference Call and Webcast Apr 28, 2004
QUEBEC CITY, April 28 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA) announced that its quarterly conference call and webcast have been scheduled for Tuesday, May 4, 2004 at 10:00 a.m. Eastern time ... AEterna Laboratories and its wholly-owned subsidiary Zentaris GmbH is a biopharmaceutical company with an extensive portfolio of marketed and development-stage products in oncology, endocrinology and infectious diseases ... For further information: AEterna Laboratories - Media... (Canada Newswire)
AEterna subsidiary Zentaris announces initiation of dose ranging study for a novel oral agent that stimulates growth hormone secretion Apr 21, 2004
QUEBEC CITY, April 21 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; NASDAQ: AELA), along with its wholly-owned subsidiary Zentaris GmbH, announced today the initiation of a dose ranging study for its EP-1572 Growth Hormone Secretagogue (GHS), a novel, orally-available peptidomimetic agent which can directly stimulate growth hormone secretion from the pituitary gland ... About AEterna Laboratories AEterna Laboratories Inc., along with its wholly-owned subsidiary Zentaris GmbH, is a... (Canada Newswire)
AEterna subsidiary Zentaris to present final results from Phase I trial of Perifosine in combination with radiotherapy at 2004 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 7, 2004
Search by Organization. 2003 Canada NewsWire Ltd.. (Canada Newswire)
AEterna subsidiary Zentaris signs new agreement with Ardana Bioscience for LHRH antagonist Teverelix Apr 2, 2004
QUEBEC CITY, Quebec, April 2 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL ; NASDAQ: AELA) announced that its wholly owned subsidiary Zentaris GmbH and Ardana Bioscience, a specialty pharmaceutical company, from Edinburgh, Scotland, have signed a new agreement for the LHRH antagonist Teverelix ... "It emphasises the commitment of Ardana towards a successful development of Teverelix. At the same time it allows for Zentaris to generate double-digit million Euro risk-free income in the... (Canada Newswire)
AEterna subsidiary Zentaris reports positive preclinical results from novel pyrazole compound - Results indicate ZEN-014 as a new candidate for the development of a potent anticancer drug Mar 31, 2004
ORLANDO, Florida, March 31 /CNW Telbec/ - AEterna Laboratories Inc. (TSX: AEL; Nasdaq: AELA) and its subsidiary Zentaris GmbH report that positive preclinical results of their novel tubulin-inhibitor ZEN-014 were presented earlier today at the American Association for Cancer Research (AACR) meeting in Orlando, Florida ... About AEterna Laboratories AEterna Laboratories Inc. along with its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company with an extensive product... (Canada Newswire)
Canada NewsWire Webcast Notification for the week of February 23, 2004 Feb 23, 2004
The Canada NewsWire Webcast Events Calendar for the week of February 23, 2004 features the following events: February 23, 2004 Company: Clearwater Seafoods Income Fund Event: Q4 Earnings Announcement Time: 4:00 PM ET URL: Company: Workbrain Corporation Event: Year End Results Time: 5:00 PM ET URL: February 24, 2004 Company: Residential Equities Real Estate Investment Trust Event: Q4 Earnings Announcement Time: 10:00 AM ET URL: Company: H;roux-Devtek Event: Q3 Earnings Announcement Time: 4:00... (Canada Newswire)
Metals led the way in bull's return Jan 2, 2004
This high-risk sector of drugs, biotechnology and laboratories clearly had its ups and downs last year. The downs included drug makers Biovail Corp. and Patheon Inc. because profits are not meeting expectations (The Globe and Mail, Canada)
AEterna updates Neovastat's cli . . . Dec 18, 2003
I am convinced that these measures, along with our solid financial position which includes CDN$75 million in cash at September 30, 2003, will greatly contribute in pursuing AEterna's growth strategy based on maximising the value of our 12-product portfolio and on acquisitions," concluded Mr. Gagnon. About AEterna Laboratories AEterna Laboratories is a biopharmaceutical company with an extensive portfolio of marketed and development-stage products in oncology, endocrinology and infectious...... (Pressemitteilung)
AEterna updates Neovastat's clinical development plan Dec 17, 2003
I am convinced that these measures, along with our solid financial position which includes $75 million in cash at September 30, 2003, will greatly contribute in pursuing AEterna's growth strategy based on maximizing the value of our 12-product portfolio and on acquisitions," concluded Mr. Gagnon. About AEterna Laboratories AEterna Laboratories is a biopharmaceutical company with an extensive portfolio of marketed and development-stage products in oncology, endocrinology and infectious...... (Pressemitteilung)
Business This Week: Manley reports on economy Nov 6, 2003
Financial reports are expected from Aeterna Laboratories, aviation training company CAE, Canadian Natural Resources, auto parts makers Linamar and Magna International, brewer Molson, Shoppers Drug Mart, hardware operator Sodisco-Howden and Terasen, formerly known as BC Gas. In Toronto, Ontario Energy Board chairman Howard Wetston speaks at a Toronto Board of Trade breakfast meeting (Toronto Star, Canada)
AEterna Laboratories Reports Third Quarter Results Nov 5, 2003
AEterna Laboratories Inc.. QUEBEC CITY, Canada, November 5 /PRNewswire/ -- - AEterna - revenues increased 55% and burn rate narrowed to $1 (PRNewswire UK (press release)
